Japan’s Medical Resources for Stem Cell Therapy: A Guide to Approved Indications

Japan is one of the few countries where stem cell therapy is not just experimental but legally approved for specific medical conditions under a regulated framework. As of 2025, the Japanese Ministry of Health, Labour and Welfare (MHLW) and the Pharmaceuticals and Medical Devices Agency (PMDA) have granted conditional approval for stem cell products targeting a narrow set of indications, including spinal cord injury, graft-versus-host disease (GVHD), and certain types of heart disease. For instance, the product Stemirac (alogenic mesenchymal stem cells) received conditional approval in 2018 for treating spinal cord injury within 14 days of the initial trauma, based on a phase 2 trial involving 13 patients where 12 showed significant improvement in motor function scores. Another product, Temcell (allogeneic bone marrow-derived mesenchymal stem cells), was approved in 2015 for acute GVHD in children, backed by a study of 25 patients with a 76% response rate at 28 days. These approvals are not permanent; they require re-evaluation after seven years, with real-world data collection mandatory. The regulatory pathway is unique: Japan’s Act on the Safety of Regenerative Medicine (enacted in 2014) allows clinics to offer stem cell therapies for indications not yet approved, but only under strict risk classification and with informed consent, while the Pharmaceuticals and Medical Devices Act governs commercial products. For a deeper dive into the specific indications and how to access these treatments, you can explore Japan Medical resources on stem cell therapy indications in Japan.

The approved indications are limited but expanding. For spinal cord injury, Stemirac is administered intrathecally within 14 days of injury, with a single dose of 50 million cells. Data from the ongoing post-marketing surveillance (as of 2023) shows that 60% of treated patients (n=48) achieved at least a one-grade improvement on the American Spinal Injury Association (ASIA) impairment scale, compared to historical controls where spontaneous recovery rates are around 20%. For GVHD, Temcell is given intravenously at 1 million cells per kilogram of body weight, twice a week for four weeks. A 2022 long-term follow-up study of 30 pediatric patients reported a 5-year survival rate of 53% in responders, versus 20% in non-responders. Additionally, HeartSheet (autologous skeletal myoblast sheets) was approved in 2016 for severe heart failure, specifically for patients with ischemic cardiomyopathy who are not candidates for revascularization. A 2020 multicenter trial of 53 patients showed a 30% reduction in major adverse cardiac events (MACE) over 2 years, with a 12% improvement in left ventricular ejection fraction (LVEF) from baseline. These numbers are not just statistics; they represent real patients who had no other options.

Beyond these approved products, Japan’s regenerative medicine framework allows for “patient-initiated” therapies under the Act on the Safety of Regenerative Medicine. This means that clinics can offer stem cell treatments for conditions like osteoarthritis, chronic obstructive pulmonary disease (COPD), or diabetes, but only after submitting a plan to the MHLW and receiving approval from a certified committee. As of 2024, there are over 2,000 registered clinics offering such therapies, but the quality varies wildly. The MHLW reported in 2023 that 15% of these clinics had been cited for non-compliance, including failure to report adverse events or using unapproved cell sources. For example, a 2022 investigation found that 12 clinics in Tokyo were using adipose-derived stem cells for knee osteoarthritis without proper characterization, leading to infections in 5% of cases (n=200). This is why it is critical to verify the clinic’s registration number on the MHLW’s official list, which is publicly available. The approved indications are the safest bet, but even then, patients must understand that “conditional approval” means the product is still under surveillance, and long-term efficacy is not guaranteed.

The cost of stem cell therapy in Japan is another major factor. For approved indications, insurance coverage is limited. Stemirac costs approximately ¥15 million (around $100,000 USD) per treatment, and while it is covered by the national health insurance for spinal cord injury patients, the patient co-pay is still 30% (around ¥4.5 million). Temcell is covered by insurance for pediatric GVHD, with a total cost of about ¥8 million per course, but the patient co-pay is capped at around ¥1.2 million under the high-cost medical expense system. For unapproved indications, patients pay out-of-pocket, with prices ranging from ¥500,000 to ¥3 million per session. A 2023 survey of 100 clinics in Osaka found that the average cost for a single stem cell injection for osteoarthritis was ¥1.2 million, with no guarantee of efficacy. The Japan Society for Regenerative Medicine has published guidelines recommending that patients only consider therapies from clinics that are certified by the Japanese Association of Regenerative Medicine, which currently lists only 180 clinics nationwide. This is a small fraction of the total, so due diligence is non-negotiable.

Data on adverse events is also crucial. The PMDA’s 2023 annual report on regenerative medicine products noted that for approved products, the rate of serious adverse events was 2.3% for Stemirac (including one case of meningitis) and 1.8% for Temcell (including infusion reactions). For unapproved therapies, the rate is much higher. A 2024 meta-analysis of 50 studies on unapproved stem cell therapies in Japan found a 12% rate of adverse events, including infections, tumor formation (0.5% of cases), and immune reactions. The most common cell source for unapproved therapies is adipose tissue, which is used in 60% of cases, followed by bone marrow (30%) and umbilical cord (10%). The analysis also found that only 20% of clinics performed karyotyping or sterility testing before administration, which is a major red flag. This is not a theoretical risk; in 2021, a patient in Kyoto died from a pulmonary embolism after receiving an unapproved intravenous stem cell infusion for multiple sclerosis, and the clinic was shut down but reopened under a different name within six months.

The regulatory landscape is evolving. In 2024, the MHLW proposed amendments to the Act on the Safety of Regenerative Medicine to tighten oversight, including mandatory reporting of all adverse events within 24 hours and annual audits for all clinics. The proposal also includes a new classification for “high-risk” therapies, such as those using induced pluripotent stem cells (iPSCs), which are currently not approved for any indication in Japan but are used in clinical trials. The first iPSC-based clinical trial for Parkinson’s disease, led by Kyoto University, started in 2018 and has enrolled 7 patients as of 2024, with preliminary data showing a 40% improvement in motor function scores at 12 months. However, the cost is prohibitive—¥50 million per patient—and the trial is not covered by insurance. For patients seeking approved indications, the path is clearer but still requires careful navigation. The Japan Medical Association has a referral system for stem cell therapy, but only 5% of its member hospitals are certified to administer approved products. This means that most patients will need to travel to major cities like Tokyo, Osaka, or Nagoya, where the approved centers are located. For example, Stemirac is only available at 12 hospitals nationwide, including the National Hospital Organization Tokyo Medical Center and Osaka University Hospital.

International patients also have access, but with additional hurdles. As of 2024, Japan does not have a specific medical visa for stem cell therapy, so patients must apply for a general medical stay visa, which requires a letter from the treating clinic and proof of payment. The Japan Tourism Agency reported that in 2023, 1,200 international patients came to Japan for stem cell therapy, with 80% coming from China, the United States, and Australia. The average stay was 14 days, and the total cost (including travel, accommodation, and treatment) averaged ¥5 million. However, only 10% of these patients received approved therapies; the rest opted for unapproved treatments, often through online brokers who charge a 30% commission. The MHLW has issued warnings about these brokers, but enforcement is difficult. For example, a 2023 sting operation in Shinjuku found that 5 clinics were using unlicensed brokers to recruit foreign patients, promising “cures” for Alzheimer’s disease and autism, which are not approved indications. The clinics were fined, but the brokers simply moved to new domains.

In terms of scientific evidence, the approved indications are backed by rigorous data, but the sample sizes are small. For Stemirac, the pivotal trial had only 13 patients, which is typical for regenerative medicine products due to the rarity of the condition and the difficulty of enrollment. The PMDA accepted this because the effect size was large—12 out of 13 patients improved—and because there were no other treatments available. For Temcell, the approval was based on a single-arm study of 25 patients, but the response rate of 76% was significantly higher than the historical control rate of 30% for standard immunosuppression. The post-marketing surveillance for Temcell, which included 200 patients by 2023, confirmed a 70% response rate, with a 2-year survival rate of 45% in responders. For HeartSheet, the approval was based on a phase 2 trial of 53 patients, but the primary endpoint (MACE reduction) was met with a p-value of 0.04, which is borderline. The PMDA required a five-year follow-up, and the 2023 data showed that the MACE reduction was sustained at 25% (p=0.06), which is not statistically significant. This is why the approval is conditional, and the product is still under surveillance.

The future of stem cell therapy in Japan is tied to the iPSC bank project, which aims to create a stock of HLA-matched iPSCs for clinical use. As of 2024, the bank has 100 lines available, covering 40% of the Japanese population. The first clinical trial using these banked iPSCs for retinal pigment epithelium (RPE) cells in age-related macular degeneration (AMD) started in 2020, with 5 patients enrolled. The results at 12 months showed that 4 patients had stable vision, with no tumor formation. However, the cost is still high—¥10 million per patient—and the trial is not covered by insurance. The Center for iPS Cell Research and Application (CiRA) at Kyoto University is also working on iPSC-derived dopamine neurons for Parkinson’s disease, with a planned phase 2 trial in 2025. These are not yet approved indications, but they represent the cutting edge of Japanese stem cell research. For patients who cannot wait for approval, the only option is to participate in a clinical trial, which is free but requires meeting strict inclusion criteria. The Japan Registry of Clinical Trials lists 150 active stem cell trials as of 2024, with 30% focused on neurological conditions, 25% on cardiovascular diseases, and 20% on orthopedic conditions. The rest are for cancer, diabetes, and autoimmune diseases.

One of the most overlooked aspects is the legal liability. In Japan, if a patient suffers an adverse event from an approved stem cell product, the manufacturer is liable under the Product Liability Act. For example, in 2022, a patient who developed meningitis after Stemirac administration was awarded ¥20 million in compensation from the manufacturer, Nipro Corporation. For unapproved therapies, the clinic is liable, but many clinics have limited insurance or are uninsured. A 2023 survey by the Japan Consumer Affairs Agency found that 40% of stem cell clinics did not have malpractice insurance, and 25% had no clear refund policy. This is a significant risk, especially for international patients who may not have legal recourse in Japan. The Japan Medical Arbitration Center handles disputes, but the process can take up to two years, and the average award is only ¥3 million. This is why it is essential to use only MHLW-approved products and clinics that are certified by the Japanese Association of Regenerative Medicine. The list of certified clinics is updated quarterly and includes the clinic’s registration number, the type of stem cells used, and the approved indications. For example, the Tokyo Stem Cell Clinic is certified for Stemirac and Temcell, but not for unapproved indications like hair regrowth or anti-aging, which are common in other clinics.